These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15911729)

  • 1. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
    Tenenbaum A; Motro M; Fisman EZ; Tanne D; Boyko V; Behar S
    Arch Intern Med; 2005 May; 165(10):1154-60. PubMed ID: 15911729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
    Brodov Y; Behar S; Boyko V; Chouraqui P
    Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
    Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
    Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
    Tenenbaum A; Motro M; Fisman EZ; Adler Y; Shemesh J; Tanne D; Leor J; Boyko V; Schwammenthal E; Behar S
    Eur Heart J; 2005 Oct; 26(19):2032-8. PubMed ID: 15872029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
    Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
    Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
    Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
    Goldenberg I; Benderly M; Goldbourt U;
    J Am Coll Cardiol; 2008 Jan; 51(4):459-65. PubMed ID: 18222357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
    Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
    Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
    Haim M; Benderly M; Tanne D; Matas Z; Boyko V; Fisman EZ; Tenenbaum A; Zimmlichman R; Battler A; Goldbourt U; Behar S
    Am Heart J; 2007 Dec; 154(6):1095-101. PubMed ID: 18035081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of obesity surgery on the metabolic syndrome.
    Lee WJ; Huang MT; Wang W; Lin CM; Chen TC; Lai IR
    Arch Surg; 2004 Oct; 139(10):1088-92. PubMed ID: 15492149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
    Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
    Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction.
    Zeller M; Steg PG; Ravisy J; Laurent Y; Janin-Manificat L; L'Huillier I; Beer JC; Oudot A; Rioufol G; Makki H; Farnier M; Rochette L; Vergès B; Cottin Y;
    Arch Intern Med; 2005 May; 165(10):1192-8. PubMed ID: 15911735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study.
    Jónsdóttir LS; Sigfússon N; Gudnason V; Sigvaldason H; Thorgeirsson G
    J Cardiovasc Risk; 2002 Apr; 9(2):67-76. PubMed ID: 12006913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men.
    Lind L; Vessby B; Sundström J
    Arterioscler Thromb Vasc Biol; 2006 Feb; 26(2):406-10. PubMed ID: 16306426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A 20-year prospective study on risk factors for myocardial infarction of 5,137 men in Capital Steel and Iron Company].
    Yue H; Gu DF; Wu XG; Yu XH; Duan XF; Wang JH; Zheng RP; Zhou J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2004 Jan; 38(1):43-6. PubMed ID: 14989905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
    de Simone G; Olsen MH; Wachtell K; Hille DA; Dahlöf B; Ibsen H; Kjeldsen SE; Lyle PA; Devereux RB
    J Hum Hypertens; 2007 Aug; 21(8):625-32. PubMed ID: 17476291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials.
    Yap YG; Duong T; Bland JM; Malik M; Torp-Pederson C; Køber L; Connolly SJ; Gallagher MM; Camm AJ
    J Hypertens; 2007 Feb; 25(2):307-13. PubMed ID: 17211237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register.
    Nilsson PM; Cederholm J; Eeg-Olofsson K; Eliasson B; Zethelius B; Fagard R; Gudbjörnsdóttir S;
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):506-12. PubMed ID: 19561510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).
    Canner PL; Furberg CD; McGovern ME
    Am J Cardiol; 2006 Feb; 97(4):477-9. PubMed ID: 16461040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.